Serum calcium and serum albumin are biomarkers that can discriminate malignant from benign pelvic masses

Michael G. Kelly, Stuart S. Winkler, Samuel S. Lentz, Steve H. Berliner, Melissa F. Swain, Halcyon G. Skinner, Gary G. Schwartz

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Biomarkers that aid in the differential diagnosis of malignant pelvic masses from benign ones prior to surgery are needed in order to triage women with malignant masses to appropriate specialist care. Because high albumin-adjusted serum calcium predicted ovarian cancer among women without evidence of disease, we hypothesized that it might predict cancer among women with pelvic masses that were evident radio graphically. Methods: We studied a cohort of 514 women with pelvic masses who underwent resection at Wake Forest University Baptist Medical Center from July 2009 through June 2013.Wedivided patients into a "training" set, to identify associations in the data, and a "testing" set, to confirm them. Data were obtained from medical records. A best fit model was selected using the Akaike Information Criterion. Results: Albumin-adjusted serum calcium was significantly higher in women with malignant versus benign masses (P = 0.0004). High normocalcemia, i.e., an albumin-adjusted serum calcium ≥ 10 mg/dL, occurred in 53% of women with malignant tumors versus 12% of benign tumors. High normocalcemia was associated with an approximately 14-fold increased risk of malignancy. The best fit model (Overa) included albumin, calcium, and nonlinear terms. Over a achieved an area under the curve of 0.83 with a sensitivity of 72% and specificity of 83%, a positive predictive value of 71% and a negative predictive value of 85%. Conclusions: A model using serum calcium and serum albumin to predict malignancy in women with pelvic masses has high sensitivity and is economical. Impact: Our model can help triage women with ovarian cancer to appropriate surgical care.

Original languageEnglish (US)
Pages (from-to)1593-1598
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Volume24
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Serum Albumin
Biomarkers
Calcium
Serum
Triage
Neoplasms
Ovarian Neoplasms
Radio
Area Under Curve
Medical Records
Albumins
Differential Diagnosis
Sensitivity and Specificity

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Serum calcium and serum albumin are biomarkers that can discriminate malignant from benign pelvic masses. / Kelly, Michael G.; Winkler, Stuart S.; Lentz, Samuel S.; Berliner, Steve H.; Swain, Melissa F.; Skinner, Halcyon G.; Schwartz, Gary G.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 24, No. 10, 01.10.2015, p. 1593-1598.

Research output: Contribution to journalArticle

Kelly, Michael G. ; Winkler, Stuart S. ; Lentz, Samuel S. ; Berliner, Steve H. ; Swain, Melissa F. ; Skinner, Halcyon G. ; Schwartz, Gary G. / Serum calcium and serum albumin are biomarkers that can discriminate malignant from benign pelvic masses. In: Cancer Epidemiology Biomarkers and Prevention. 2015 ; Vol. 24, No. 10. pp. 1593-1598.
@article{6ee9e47ac2d54369bd61bb4f60451274,
title = "Serum calcium and serum albumin are biomarkers that can discriminate malignant from benign pelvic masses",
abstract = "Background: Biomarkers that aid in the differential diagnosis of malignant pelvic masses from benign ones prior to surgery are needed in order to triage women with malignant masses to appropriate specialist care. Because high albumin-adjusted serum calcium predicted ovarian cancer among women without evidence of disease, we hypothesized that it might predict cancer among women with pelvic masses that were evident radio graphically. Methods: We studied a cohort of 514 women with pelvic masses who underwent resection at Wake Forest University Baptist Medical Center from July 2009 through June 2013.Wedivided patients into a {"}training{"} set, to identify associations in the data, and a {"}testing{"} set, to confirm them. Data were obtained from medical records. A best fit model was selected using the Akaike Information Criterion. Results: Albumin-adjusted serum calcium was significantly higher in women with malignant versus benign masses (P = 0.0004). High normocalcemia, i.e., an albumin-adjusted serum calcium ≥ 10 mg/dL, occurred in 53{\%} of women with malignant tumors versus 12{\%} of benign tumors. High normocalcemia was associated with an approximately 14-fold increased risk of malignancy. The best fit model (Overa) included albumin, calcium, and nonlinear terms. Over a achieved an area under the curve of 0.83 with a sensitivity of 72{\%} and specificity of 83{\%}, a positive predictive value of 71{\%} and a negative predictive value of 85{\%}. Conclusions: A model using serum calcium and serum albumin to predict malignancy in women with pelvic masses has high sensitivity and is economical. Impact: Our model can help triage women with ovarian cancer to appropriate surgical care.",
author = "Kelly, {Michael G.} and Winkler, {Stuart S.} and Lentz, {Samuel S.} and Berliner, {Steve H.} and Swain, {Melissa F.} and Skinner, {Halcyon G.} and Schwartz, {Gary G.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1158/1055-9965.EPI-15-0443",
language = "English (US)",
volume = "24",
pages = "1593--1598",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Serum calcium and serum albumin are biomarkers that can discriminate malignant from benign pelvic masses

AU - Kelly, Michael G.

AU - Winkler, Stuart S.

AU - Lentz, Samuel S.

AU - Berliner, Steve H.

AU - Swain, Melissa F.

AU - Skinner, Halcyon G.

AU - Schwartz, Gary G.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Background: Biomarkers that aid in the differential diagnosis of malignant pelvic masses from benign ones prior to surgery are needed in order to triage women with malignant masses to appropriate specialist care. Because high albumin-adjusted serum calcium predicted ovarian cancer among women without evidence of disease, we hypothesized that it might predict cancer among women with pelvic masses that were evident radio graphically. Methods: We studied a cohort of 514 women with pelvic masses who underwent resection at Wake Forest University Baptist Medical Center from July 2009 through June 2013.Wedivided patients into a "training" set, to identify associations in the data, and a "testing" set, to confirm them. Data were obtained from medical records. A best fit model was selected using the Akaike Information Criterion. Results: Albumin-adjusted serum calcium was significantly higher in women with malignant versus benign masses (P = 0.0004). High normocalcemia, i.e., an albumin-adjusted serum calcium ≥ 10 mg/dL, occurred in 53% of women with malignant tumors versus 12% of benign tumors. High normocalcemia was associated with an approximately 14-fold increased risk of malignancy. The best fit model (Overa) included albumin, calcium, and nonlinear terms. Over a achieved an area under the curve of 0.83 with a sensitivity of 72% and specificity of 83%, a positive predictive value of 71% and a negative predictive value of 85%. Conclusions: A model using serum calcium and serum albumin to predict malignancy in women with pelvic masses has high sensitivity and is economical. Impact: Our model can help triage women with ovarian cancer to appropriate surgical care.

AB - Background: Biomarkers that aid in the differential diagnosis of malignant pelvic masses from benign ones prior to surgery are needed in order to triage women with malignant masses to appropriate specialist care. Because high albumin-adjusted serum calcium predicted ovarian cancer among women without evidence of disease, we hypothesized that it might predict cancer among women with pelvic masses that were evident radio graphically. Methods: We studied a cohort of 514 women with pelvic masses who underwent resection at Wake Forest University Baptist Medical Center from July 2009 through June 2013.Wedivided patients into a "training" set, to identify associations in the data, and a "testing" set, to confirm them. Data were obtained from medical records. A best fit model was selected using the Akaike Information Criterion. Results: Albumin-adjusted serum calcium was significantly higher in women with malignant versus benign masses (P = 0.0004). High normocalcemia, i.e., an albumin-adjusted serum calcium ≥ 10 mg/dL, occurred in 53% of women with malignant tumors versus 12% of benign tumors. High normocalcemia was associated with an approximately 14-fold increased risk of malignancy. The best fit model (Overa) included albumin, calcium, and nonlinear terms. Over a achieved an area under the curve of 0.83 with a sensitivity of 72% and specificity of 83%, a positive predictive value of 71% and a negative predictive value of 85%. Conclusions: A model using serum calcium and serum albumin to predict malignancy in women with pelvic masses has high sensitivity and is economical. Impact: Our model can help triage women with ovarian cancer to appropriate surgical care.

UR - http://www.scopus.com/inward/record.url?scp=84942927464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942927464&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-15-0443

DO - 10.1158/1055-9965.EPI-15-0443

M3 - Article

C2 - 26184501

AN - SCOPUS:84942927464

VL - 24

SP - 1593

EP - 1598

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 10

ER -